Experts in predictive medicine technology have joined University of Leeds innovation community Nexus as it prepares for international expansion.
The new company – EDH-AI – which specialises in research and predictive analysis into chronic illnesses, launched its world-leading preventative healthcare business at a special event in Nexus for members, guests and investors recently.
Founded in France four years ago as ToxSeek, the company was born from the meeting of a toxicology expert, a chemist, a public health specialist and a high-tech entrepreneur and is now poised to seek major funding for international growth from its new UK base.
“The Nexus community was an obvious choice for us to base the next stage of our growth internationally and Leeds is increasingly recognised across Europe as a leading innovation cluster for healthcare and healthtech innovation,” said Matthieu Davoli, EDH-AI Director.
“One of my co-directors, Nabil Sadeg, gained his MSC in computer science at the University of Leeds and Nexus’ links with the University and wider networks, particularly in the health and wellbeing sectors, means that we have ready access to the brilliant academic minds and talent there, which will be fundamental as we expand our services.”
Dr Martin Stow, Nexus Chairman and Director, comments: “We’re delighted to welcome EDH-AI to the Nexus community, where they join a host of member businesses who are leading transformative change in healthcare, particularly through the innovative use of digital technology.
“We are looking forward to helping them tell their incredible story to other businesses, stakeholders and potential investors as they move to the next stage of their growth and development.”
EDH-AI will build a new automated laboratory at Nexus, dedicated to the analysis of toxins and proteins in patients with long-term health conditions.
Sharing their expertise with university research teams, academic institutions and the NHS, the company aims to develop personalised plans for patients to help them manage their illness and alleviate symptoms.
The company is seeking funding through DeFi investment, which will be converted into further analysis and online consultation for patients. Investors will be able to make the analyses available for family members or donate them to medical research.
